Dose summaries

Dosing patterns by compound and indication

Curated summaries of source-structured dose rows from Blossom's clinical research database. Each page keeps source units, coverage, and limitations visible so dosing patterns stay tied to the studies that reported them.

Report pages
6
Linked trials
213
Dose rows
298

Published dose summaries

These reports are generated from normalized trial intervention data and stored as editable Sanity content. Mixed units and sparse rows are disclosed rather than converted into false equivalents.

Open first report

Esketamine for Depressive Disorders

Esketamine for Depressive Disorders: dose summaries

Esketamine clinical studies for Depressive Disorders include 24 structured dose rows across 20 linked trials. Common source-reported dose patterns include 84 mg, 0.2 mg/kg, 56 mg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
20
Dose rows
24

Source-reported patterns

84 mg0.2 mg/kg56 mg84 mg
84 mg, 0.2 mg/kg, 56 mg

Ketamine for Depressive Disorders

Ketamine for Depressive Disorders: dose summaries

Ketamine clinical studies for Depressive Disorders include 118 structured dose rows across 79 linked trials. Common source-reported dose patterns include 0.5 mg/kg, 0.5-0.75 mg/kg, 0.25 mg/kg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
79
Dose rows
118

Source-reported patterns

0.5 mg/kg0.5 mg/kg0.5 mg/kg0.5-0.75 mg/kg
0.5 mg/kg, 0.5-0.75 mg/kg

MDMA for PTSD

MDMA for PTSD: dose summaries

MDMA clinical studies for PTSD include 26 structured dose rows across 18 linked trials. Common source-reported dose patterns include 125 mg, 25 mg, 80-180 mg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
18
Dose rows
26

Source-reported patterns

125 mg125 mg25 mg80-180 mg
125 mg, 25 mg, 80-180 mg

Psilocybin for Anxiety Disorders

Psilocybin for Anxiety Disorders: dose summaries

Psilocybin clinical studies for Anxiety Disorders include 52 structured dose rows across 37 linked trials. Common source-reported dose patterns include 25 mg, 10 mg, 15-25 mg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
37
Dose rows
52

Source-reported patterns

25 mg25 mg10 mg15-25 mg
25 mg, 10 mg, 15-25 mg

Psilocybin for Depressive Disorders

Psilocybin for Depressive Disorders: dose summaries

Psilocybin clinical studies for Depressive Disorders include 56 structured dose rows across 43 linked trials. Common source-reported dose patterns include 25 mg, 1 mg, 10 mg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
43
Dose rows
56

Source-reported patterns

25 mg25 mg1 mg10 mg
25 mg, 1 mg, 10 mg

Psilocybin for Substance Use Disorders (SUD)

Psilocybin for Substance Use Disorders (SUD): dose summaries

Psilocybin clinical studies for Substance Use Disorders (SUD) include 22 structured dose rows across 16 linked trials. Common source-reported dose patterns include 25 mg, 0.1 mg/kg, 0.3 mg/kg. Interpret these as descriptive trial protocols, not treatment recommendations.

Linked trials
16
Dose rows
22

Source-reported patterns

25 mg0.1 mg/kg0.3 mg/kg0.3-0.4 mg/kg
25 mg, 0.1 mg/kg, 0.3 mg/kg

How to interpret these pages

The summaries describe dosing protocols reported in clinical studies. They preserve source units and route details where available, and they should not be read as clinical dosing recommendations or direct cross-trial comparability claims.